Advertisement

Exkurs: Neurogenetik

  • H. Reichmann

Zusammenfassung

Während der letzten Dekade standen zunehmend Untersuchungen degenerativer Faktoren sowie von Umwelteinflüssen bezüglich der Pathogenese des idiopathischen Parkinsonsyndroms (IPS) im Vordergrund. Toxische Umweltfaktoren wurden weltweit gesucht, da Tiermodelle mit Toxinen wie MPTP oder TaClo den Gedanken, daß Neurotoxine zum Parkinsonsyndrom führen, nahelegten. Es ist trotz dieser wichtigen Hinweise aber bei weitem nicht sicher, daß das IPS durch ein Neurotoxin induziert wird. Andere pathogenetische überlegungen versuchen, den selektiven Untergang dopaminerger Neurone in der Substantia nigra auf neurodegenerative Vorgänge wie Störungen des Energiestoffwechsels, Auswirkungen von oxidativem Streß oder vielleicht sogar apoptotischen Abbau zurückzuführen. über all diesen wichtigen Erkenntnissen sollten aber genetische Faktoren nicht außer Acht gelassen werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alonso ME, Otero E (1986) Parkinson’s disease: a genetic study. Can J Neurol Sci 13: 248–251PubMedGoogle Scholar
  2. Carero-Valenzuela R, Lindblad K, Payami H et al. (1995) No evidence for association of familial Parkinson disease with CAG repeat expansion. Neurology 45: 1760–1763PubMedCrossRefGoogle Scholar
  3. Gasser T, Wszolek ZK, Trofatter J, Ozelius L, Uitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, BREAKEFIELD-XO (1994) Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 36: 387–396PubMedCrossRefGoogle Scholar
  4. Gasser T, Müller-Myhsok B, Wszolek Z et al. (1997) Genetic complexity and Parkinson’s disease. Science 277: 388–389PubMedGoogle Scholar
  5. Gasser T, Müller-Myhsok B, Wszolek Z et al. (1998) A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nature Genet 18: 262–265PubMedCrossRefGoogle Scholar
  6. Golbe LI (1993) The genetics of Parkinson’s disease. Rev Neurosci 4: 1–16PubMedCrossRefGoogle Scholar
  7. Ikebe S, Tanaka M, Ozawa T (1995) Point mutations of mitochondrial genome in Parkinson’s disease. Brain Res Mol Brain Res 28: 281–295PubMedCrossRefGoogle Scholar
  8. Janetzky B, Hauck S, Youdim MBH et al. (1994) Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson’s disease. Neurosci Lett 169: 126–128PubMedCrossRefGoogle Scholar
  9. Kitada T, Asakawa S, Hattori N et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605–608PubMedCrossRefGoogle Scholar
  10. Lazzarini AM, Myers RH, Zimmermann TR et al. (1994) A clinical genetic study of Parkinson’s disease: evidence for dominant transmission. Neurology 44: 499–506PubMedCrossRefGoogle Scholar
  11. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H (1990) Normal mitochondrial genome in brain from patients with Parkinson’s disease and complex I deficiency. J Neurochem 55: 1810–1812PubMedCrossRefGoogle Scholar
  12. Marder K, Maestre G, Cote L, Mejia H, Alfaro B, Halim A, Tang M, Tycko B, Mayeux R (1994) The apolipoprotein epsilon 4 allele in Parkinson’s disease with and without dementia. Neurology 44: 1330–1331PubMedCrossRefGoogle Scholar
  13. Markopoulou K, Wszolek ZK, Pfeiffer RF (1995) A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol 38: 373–378PubMedCrossRefGoogle Scholar
  14. Payami H, Larsen K, Bernard S, Nutt J (1994) Increasod risk of Parkinson’s disease in parents and siblings of patients. Ann Neurol 336: 659–661CrossRefGoogle Scholar
  15. Payami H, Bernard S, Larsen K, Kaye J, Nutt J (1995) Genetic acticipation in Parkinson’s disease. Neurology 45: 135–138PubMedCrossRefGoogle Scholar
  16. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nuss-Baum RL, Duvoisin RC (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274: 1197–1199PubMedCrossRefGoogle Scholar
  17. Reichmann H, Janetzky B, Bischof F, Seibel P, Schols L, Kuhn W, Przuntek H (1994) Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle from patients with idiopathic Parkinson’s syndrome. Eur Neurol 34: 263–267PubMedCrossRefGoogle Scholar
  18. Rubinstein DC, Hanlon CS, Irving RM, Goodburn S, Evans DG, Kellar-Wood H, Xuereb JH, Bandmann O, Harding AE (1994) Apo E genotypes in multiple sclerosis, Parkinson’s disease, schwannomas an late-onset Alzheimer’s disease. Mol Cell Probes 8: 519–525CrossRefGoogle Scholar
  19. Schapira AHV, Mann VM, Cooper JM et al. (1990) Anatomic and disease specificity of NADH C0Q1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 55: 2142–2145PubMedCrossRefGoogle Scholar
  20. Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R et al. (1993) Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17: 171–184PubMedCrossRefGoogle Scholar
  21. Vieregge P (1994) Genetic factors in the etiology of idiopathic Parkinson’s disease. J Neural Transm [PD-Sect] 8J Neural Transm [PD-Sect]: 1–37CrossRefGoogle Scholar
  22. Wallace DC (1994) Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci USA 91: 8739–8746PubMedCrossRefGoogle Scholar
  23. Waters CH, Takahashi H, Wilhelmsen KC, Shubin R, Snow BJ (1993) Phenotypic expression of X-linked dystonia parkinsonism (Lubag) in two women. Neurology 43: 1555–1558PubMedCrossRefGoogle Scholar
  24. Zweig RM, Singh A, Cardillo JE, Langston JW (1992) The familial occurrence of Parkinson’s disease. Lack of evidence for maternal inheritance. Arch Neurol 49: 1205–1207PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • H. Reichmann

There are no affiliations available

Personalised recommendations